The Medicines and Healthcare products Regulatory Agency has authorised Inqlexzo, an intravesical delivery system containing gemcitabine, for adults with BCG-unresponsive high-risk non-muscle-invasive bladder cancer who are either not eligible for radical cystectomy or have decided not to undergo the operation. The marketing authorisation was granted on 24 June 2026 to Janssen-Cilag Ltd. For the UK treatment pathway, the decision adds a licensed option for a patient group with limited alternatives once BCG treatment is no longer effective. The MHRA announcement places the product within a bladder-sparing setting, which will be particularly relevant in cases where surgery is not suitable or is declined.
High-risk non-muscle-invasive bladder cancer has not spread into the muscle layer of the bladder, but it carries a substantial risk of recurrence or progression. That is why the condition sits at an important point in cancer care, where clinicians are trying to control disease while also preventing a move to more advanced stages. The press notice is also clear about the patient group covered by the authorisation. It applies to adults with BCG-unresponsive disease, meaning patients whose cancer has not responded adequately to Bacillus Calmette-Guérin therapy. In plain terms, this is a group in which standard bladder-preserving treatment has already proved insufficient.
Inqlexzo is administered directly into the bladder by a healthcare professional using a catheter. The delivery system is designed to provide sustained local release of gemcitabine over around three weeks, after which it is removed by cystoscopy. The authorised treatment schedule starts with administration every three weeks for the first six months. After that, the interval moves to every 12 weeks for up to 18 months, unless the cancer recurs, progresses or the patient experiences toxicity that makes continued treatment unacceptable. That structure means the medicine is not a one-off intervention but part of a monitored specialist urology programme.
The authorisation is supported by a clinical study in adults with BCG-unresponsive high-risk non-muscle-invasive bladder cancer with carcinoma in situ. According to the MHRA, 82 per cent of patients achieved a complete response, while 51 per cent of those who responded maintained that response for at least 12 months. Those results form the evidential basis for the 24 June 2026 regulatory decision. For clinicians, the next practical reference point will be the product documentation: the MHRA said the Summary of Product Characteristics and the patient information leaflet would be published on the agency's products website within seven days of approval.
The adverse reactions listed in the announcement are mainly urinary and bladder-related, which is consistent with a treatment delivered locally into the bladder. The most commonly reported reactions were urinary frequency, urinary tract infection, dysuria, urinary urgency, urinary tract pain, haematuria and bladder irritation. Julian Beach, the MHRA's interim executive director of healthcare quality and access, said the agency would continue to monitor the product's safety and effectiveness closely. As with other newly authorised medicines, post-market reporting remains part of the regulatory picture, and patients who suspect a side effect are advised to speak to a healthcare professional and use the Yellow Card scheme.
From a medicines policy perspective, the decision also shows the continued use of the International Recognition Procedure in the UK system. The MHRA said the product was submitted and approved under IRP Route B, indicating that the application moved through a recognition-based regulatory route rather than a wholly standalone national assessment. The immediate effect of the authorisation is that Inqlexzo becomes an approved UK medicine for its licensed indication. For patients and providers, that does not by itself determine how quickly the treatment is used in practice, but it does establish a new regulated option in a difficult treatment setting where bladder preservation may be a significant consideration.